Journals / Turkish Journal of Pediatrics / 2018 / Cilt: 60 - Sayı: 6

C o g n i t i v e a n d b e h a v i o r a l i m p a i r m e n t i n m i l d hyperphenylalaninemia

Pages
617–624
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Since the results demonstratedthat children with untreated Phe levels between 240-360 μmol/L are at higherrisk for cognitive and attention-related problems, lowering the “safe” upperPhe level should be considered.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:As elevated phenylalanine (Phe) is detrimental to brain functions, determininga safe upper limit of blood Phe is important for initiation of treatment plansand setting Phe targets in hyperphenlalaninemic patients.
📊
Key Findings & Data:It is accepted thatPhe levels below 360 μmol/L does not impair brain function and hence doesnot require treatment.
💡
Conclusion & Impact:Since the results demonstratedthat children with untreated Phe levels between 240-360 μmol/L are at higherrisk for cognitive and attention-related problems, lowering the “safe” upperPhe level should be considered.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

As elevated phenylalanine (Phe) is detrimental to brain functions, determininga safe upper limit of blood Phe is important for initiation of treatment plansand setting Phe targets in hyperphenlalaninemic patients. It is accepted thatPhe levels below 360 μmol/L does not impair brain function and hence doesnot require treatment. Therefore, we aimed to compare cognitive functions andattention-related problems among healthy children and untreated patients withhyperphenylalaninemia (HPA). This study included 41 hyperphenylalaninemicpatients (“all HPA group”) aged 6-16 years with untreated blood Phe between240 and 600 μmol/L and 29 healthy controls. “All HPA group” was furtherdivided into 2 subgroups according to their lifetime median blood Phe levels as“Phe 360-600 μmol/L” and “Phe 240-360 μmol/L” groups. Wechsler IntelligenceScale for Children–IV (WISC-IV), Conners’ Continuous Performance Test (CPT),Strength and Difficulties Questionnaire (SDQ) and Schedule for AffectiveDisorders and Schizophrenia for School-Age Children: Present and LifetimeVersion (K-SADS-PL) were performed as a comprehensive neurocognitive,attention and behavioral assessment. The study illustrated that “all HPA”patients had significantly lower scores on all WISC-IV indexes compared tocontrols, except for Working Memory. Both “Phe 360-600 μmol/L” and “Phe240-360 μmol/L” subgroups had lower Full Scale intelligence quotient (IQ) andVerbal Comprehension scores compared to controls. “All HPA” patients alsohad longer reaction times and more peer problems than controls, indicatingattention deficits and behavioral problems. Since the results demonstratedthat children with untreated Phe levels between 240-360 μmol/L are at higherrisk for cognitive and attention-related problems, lowering the “safe” upperPhe level should be considered.

🔖

Cite This Article

EVİNÇ, Ş. G., PEKTAŞ, E., ÖZDEMİR, D. F., YILDIZ, Y., KARABONCUK, Y., GURBUZ, B. B., DURSUN, A., TOKATLI, A., COŞKUN, T. (2018). C o g n i t i v e a n d b e h a v i o r a l i m p a i r m e n t i n m i l d hyperphenylalaninemia. Turkish Journal of Pediatrics, Cilt: 60 - Sayı: 6, 617–624. https://ajindex.com/articles/412137

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. National Institutes of Health Consensus Development P. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000. Pediatrics 2001; 108: 972-982. de Groot MJ, Hoeksma M, Blau N, Reijngoud DJ, van Spronsen FJ. Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses. Mol Genet Metab 2010; 99(Suppl 1): S86-S89. Camp KM, Parisi MA, Acosta PB, et al. Phenylketonuria Scientific Review Conference: state of the science and future research needs. Mol Genet Metab 2014; 112: 87-122. van Spronsen FJ, van Wegberg AM, Ahring K, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol 2017; 5: 743-756.
  2. Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med 2014; 16: 188-200.
  3. Ozalp I, Coskun T, Tokatli A, et al. Newborn PKU screening in Turkey: at present and organization for future. Turk J Pediatr 2001; 43: 97-101.
  4. Costello PM, Beasley MG, Tillotson SL, Smith I. Intelligence in mild atypical phenylketonuria. Eur J Pediatr 1994; 153: 260-263.
  5. Weglage J, Pietsch M, Feldmann R, et al. Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. Pediatr Res 2001; 49: 532-536.
  6. Jahja R, Huijbregts SC, de Sonneville LM, van der Meere JJ, van Spronsen FJ. Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria. J Pediatr 2014; 164: 895-899. Wechsler D. Wechsler Intelligence Scale for Children– Fourth Edition technical and interpretive manua. San Antonio, TX: Psychological Corporation; 2003.
  7. Uluç S, Öktem F, Erden G, Gençöz T, Sezgin N. Wechsler Çocuklar İçin Zekâ Ölçeği-IV: Klinik bağlamda zekânın değerlendirilmesinde Türkiye için yeni bir dönem. Türk Psikoloji Yazıları 2011; 14: 49-57.
  8. Conners CK, Epstein JN, Angold A, Klaric J. Continuous performance test performance in a normative epidemiological sample. J Abnorm Child Psychol 2003; 31: 555-562. Conners’ Continuous Performance Test II: Computer Program for Windows Technical Guide and Software Manual. North Twanda, NY: Multi-Health Systems; 2000. Goodman R. The Strengths and Difficulties Questionnaire: a research note. J Child Psychol Psychiatry 1997; 38: 581-586.
  9. Güvenir T, Özbek A, Baykara B, Arkar H, Şentürk B, İncekaş S. Güçler ve Güçlükler Anketi’nin (GGA) Türkçe uyarlamasının psikometrik özellikleri. Çocuk ve Gençlik Ruh Sağliği